Triple Hormone Agonist Retatrutide Drives 25% Weight Loss in Phase 3 Trial
The TRIUMPH-1 trial shows retatrutide achieves up to 25% body weight reduction and meaningfully improves knee pain and sleep apnea in adults with obesity.
Summary
Retatrutide — a once-weekly injectable that activates three hormone receptors (GIP, GLP-1, and glucagon) — was tested in a large phase 3 trial involving 2,339 adults with obesity but without diabetes. Over 80 weeks, participants receiving the highest dose lost an average of 25% of their body weight, compared to just 3.9% with placebo. Beyond weight loss, those with knee osteoarthritis reported substantially reduced pain, and those with obstructive sleep apnea saw dramatic reductions in breathing events per hour. Gastrointestinal side effects were the most common complaints. These results position retatrutide as potentially the most powerful weight-loss drug tested to date, with meaningful downstream benefits for two major obesity-related conditions that significantly affect healthspan and quality of life.
Detailed Summary
Obesity is a primary driver of accelerated biological aging, fueling conditions from cardiovascular disease to osteoarthritis and sleep apnea — all of which compress healthspan. Retatrutide, developed by Eli Lilly, represents a new pharmacological frontier by simultaneously activating three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple-agonist mechanism is hypothesized to produce additive metabolic effects beyond what dual GIP/GLP-1 agonists like tirzepatide already achieve.
The TRIUMPH-1 trial was a phase 3, randomized, double-blind, placebo-controlled study enrolling 2,339 adults with obesity (without diabetes). Participants received once-weekly subcutaneous injections of retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks. Primary endpoints included percent body weight change, knee pain scores in those with osteoarthritis, and apnea-hypopnea index in those with obstructive sleep apnea.
Results were striking across all doses. Mean body weight declined by 17.6%, 23.7%, and 25.0% for the 4 mg, 9 mg, and 12 mg groups respectively, versus 3.9% for placebo — differences exceeding 19 and 21 percentage points for the two primary dose comparisons. Among the 574 participants with knee osteoarthritis, pain scores fell by roughly 3.5–3.6 points on a 10-point scale versus 1.9 for placebo. Among the 243 participants with obstructive sleep apnea, breathing events per hour fell by 34.3 at the 9 mg dose versus 9.9 for placebo. All primary comparisons reached p<0.001. The most common adverse events were gastrointestinal in nature, consistent with the drug class.
For longevity-focused clinicians and health-conscious individuals, retatrutide's profile is notable not just for the magnitude of weight loss but for its simultaneous improvement of mechanistically distinct obesity complications. Reduced joint pain and improved sleep architecture both independently predict better long-term functional capacity. However, this summary is based on the abstract alone, long-term safety data beyond 80 weeks are not yet available, and the trial excluded people with diabetes.
Key Findings
- Retatrutide 12 mg produced 25% mean body weight loss over 80 weeks versus 3.9% with placebo.
- Knee osteoarthritis pain scores fell ~1.6–1.8 points more than placebo (on a 10-point scale).
- Obstructive sleep apnea events per hour dropped by 34.3 at 9 mg versus 9.9 with placebo.
- All primary efficacy endpoints reached p<0.001; gastrointestinal effects were the main side effects.
- Triple-receptor agonism (GIP + GLP-1 + glucagon) may explain weight loss exceeding current dual agonists.
Methodology
TRIUMPH-1 was a phase 3, randomized, double-blind, placebo-controlled trial in 2,339 adults with obesity without diabetes, running 80 weeks across three active dose arms (4 mg, 9 mg, 12 mg). Primary weight endpoints used an intention-to-treat treatment-regimen estimand; osteoarthritis and sleep apnea endpoints used a hybrid-treatment estimand with hypothetical failure strategy for intercurrent events, with ITT results also reported.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; detailed safety, subgroup, and metabolic biomarker data are unavailable for review. The trial excluded adults with diabetes, limiting generalizability to a large segment of the obese population. Long-term safety and durability of weight loss beyond 80 weeks remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: